Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea M Gross

Showing results (1-10 of 51) with videos related to

Pageof 6
Sort By:
Current Problems in Cancer|July 12, 2021
Using real world data to support regulatory approval of drugs in rare diseases: A review of opportunities, limitations & a case exampleAndrea M Gross
Neuro-Oncology Advances|July 10, 2020
Clinical trial design in neurofibromatosis type 1 as a model for other tumor predisposition syndromesAndrea M Gross, Brigitte C Widemann
Child'S Nervous System : Chns : Official Journal of the International Society for Pediatric Neurosurgery|July 2, 2020
Current status of MEK inhibitors in the treatment of plexiform neurofibromasAndrea M Gross, Eva Dombi, Brigitte C Widemann
Neurology|July 7, 2021
Neurofibromatosis Clinical Trials-REiNS Collaboration 2020 Recommendations: Looking Back and Moving AheadAndrea M Gross, Scott R Plotkin, Brigitte C Widemann, et al.
Clinical Trials (London, England)|September 30, 2023
Advancing neurofibromatosis and schwannomatosis clinical trial design: Consensus recommendations from the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International CollaborationVanessa L Merker, Andrea M Gross, Brigitte C Widemann, et al.
Neuro-Oncology Advances|July 25, 2025
Selumetinib in pediatric patients with neurofibromatosis type 1 and plexiform neurofibroma: Propensity score analysis of SPRINT vs. natural history control armAyo Adeyemi, Andrea M Gross, Andrea Baldwin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2025
Challenges in Assessing Response in Clinical Trials for Neurofibromatosis Type 1 Plexiform NeurofibromasEva Dombi, Andrea M Gross, Brigitte C Widemann, et al.
Future Oncology (London, England)|June 13, 2024
Selumetinib for children with neurofibromatosis type 1 and plexiform neurofibromas: A plain language summary of SPRINTAndrea M Gross, Colette Achée, Sarah E Hart, et al.
Neuro-Oncology Advances|December 31, 2025
Malignant peripheral nerve sheath tumors in neurofibromatosis type 1 arise from distinct nodular lesions: A retrospective imaging analysisJohannes Salamon, Brigitte C Widemann, Andrea M Gross, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 6, 2024
Contemporary Approach to Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath TumorsAngela C Hirbe, Carina A Dehner, Eva Dombi, et al.
Pageof 6

Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
Current Problems in Cancer|July 12, 2021
Using real world data to support regulatory approval of drugs in rare diseases: A review of opportunities, limitations & a case exampleAndrea M Gross
Neuro-Oncology Advances|July 10, 2020
Clinical trial design in neurofibromatosis type 1 as a model for other tumor predisposition syndromesAndrea M Gross, Brigitte C Widemann
Child'S Nervous System : Chns : Official Journal of the International Society for Pediatric Neurosurgery|July 2, 2020
Current status of MEK inhibitors in the treatment of plexiform neurofibromasAndrea M Gross, Eva Dombi, Brigitte C Widemann
Neurology|July 7, 2021
Neurofibromatosis Clinical Trials-REiNS Collaboration 2020 Recommendations: Looking Back and Moving AheadAndrea M Gross, Scott R Plotkin, Brigitte C Widemann, et al.
Clinical Trials (London, England)|September 30, 2023
Advancing neurofibromatosis and schwannomatosis clinical trial design: Consensus recommendations from the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International CollaborationVanessa L Merker, Andrea M Gross, Brigitte C Widemann, et al.
Neuro-Oncology Advances|July 25, 2025
Selumetinib in pediatric patients with neurofibromatosis type 1 and plexiform neurofibroma: Propensity score analysis of SPRINT vs. natural history control armAyo Adeyemi, Andrea M Gross, Andrea Baldwin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2025
Challenges in Assessing Response in Clinical Trials for Neurofibromatosis Type 1 Plexiform NeurofibromasEva Dombi, Andrea M Gross, Brigitte C Widemann, et al.
Future Oncology (London, England)|June 13, 2024
Selumetinib for children with neurofibromatosis type 1 and plexiform neurofibromas: A plain language summary of SPRINTAndrea M Gross, Colette Achée, Sarah E Hart, et al.
Neuro-Oncology Advances|December 31, 2025
Malignant peripheral nerve sheath tumors in neurofibromatosis type 1 arise from distinct nodular lesions: A retrospective imaging analysisJohannes Salamon, Brigitte C Widemann, Andrea M Gross, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 6, 2024
Contemporary Approach to Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath TumorsAngela C Hirbe, Carina A Dehner, Eva Dombi, et al.
Pageof 6